Triple-combination rilpivirine, emtricitabine, and tenofovir (Complera™/Eviplera™) in the treatment of HIV infection

Patient Preference and Adherence

Volumn 7, Issue , 2013, Pages 531-542

  Bernardini, Claudia ^a   Maggiolo, Franco ^a  

^a AO Papa Giovanni XXIII   (Italy)

Author keywords

HIV; Once daily; Rilpivirine or RPV; Single tablet regimen; Treatment na ve

Indexed keywords

ABACAVIR PLUS LAMIVUDINE; ATAZANAVIR PLUS RITONAVIR; DARUNAVIR PLUS RITONAVIR; EFAVIRENZ PLUS EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; EMTRICITABINE PLUS RILPIVIRINE PLUS TENOFOVIR DISOPROXIL; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; LAMIVUDINE PLUS NEVIRAPINE PLUS TENOFOVIR DISOPROXIL; LOPINAVIR PLUS RITONAVIR; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RALTEGRAVIR; RIBAVIRIN; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ABDOMINAL PAIN; ANTIVIRAL ACTIVITY; AREA UNDER THE CURVE; BRONCHOPNEUMONIA; BURKITT LYMPHOMA; CD4+ T LYMPHOCYTE; COST EFFECTIVENESS ANALYSIS; DEPRESSION; DIZZINESS; DNA REPLICATION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG POTENCY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; HEALTH CARE SYSTEM; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INSOMNIA; LIPID BLOOD LEVEL; MAXIMUM PLASMA CONCENTRATION; MENTAL DISEASE; NAUSEA; NEUROLOGIC DISEASE; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW;

EID: 84879396200     PISSN: None     EISSN: 1177889X     Source Type: Journal    
DOI: 10.2147/PPA.S28797     Document Type: Review

References (52)

1. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. Department of Health and Human Services [updated February 12, 2013]. Available from: http://aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdf. Accessed February 25, 2013.
2. Maltêz F, Doroana M, Branco T, Valente C. Recent advances in antiretroviral treatment and prevention in HIV-infected patients. Curr Opin HIV AIDS. 2011;6 Suppl 1:S21-S30.
3. Cohen MS, Chen YQ, McCauley M, et al; HPTN 052 Study Team. Prevention of HIV-1infection with early antiretroviral therapy. N Engl J Med. 2011;365(6):493-505.
4. Thompson MA, Aberg JA, Hoy JF, et al. Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel. JAMA. 2012;308(4):387-402.
5. Hasse B, Ledergerber B, Furrer H, et al; Swiss HIV Cohort Study. Morbidity and aging in HIV-infected persons: the Swiss HIV cohort study. Clin Infect Dis. 2011;53(11):1130-1139.
6. Krentz HB, Cosman I, Lee K, Ming JM, Gill MJ. Pill burden in HIV infection: 20 years of experience. Antivir Ther. 2012;17(5):833-840.
7. Marzolini C, Back D, Weber R, et al; Swiss HIV Cohort Study Members. Ageing with HIV: medication use and risk for potential drug-drug interactions. J Antimicrob Chemother. 2011;66(9):2107-2111.
8. Llibre JM, Arribas JR, Domingo P, et al; Spanish Group for FDAC Evaluation. Clinical implications of fixed-dose coformulations of antiretrovirals on the outcome of HIV-1 therapy. AIDS. 2011;25(14): 1683-1690.
9. Sax PE, Meyers JL, Mugavero M, Davis KL. Adherence to antiretroviral treatment and correlation with risk of hospitalization among commercially insured HIV patients in the United States. PLoS One. 2012;7(2):e31591.
10. Tibotec Pharmaceuticals; Edurant™ (rilpivirine) tablets [prescribing information]. Raritan, NJ: 2011.
11. Ghosn J, Chaix ML, Delaugerre C. HIV-1 resistance to first-and second-generation non-nucleoside reverse transcriptase inhibitors. AIDS Rev. 2009;11(3):165-173.
12. Deeks ED, Keating GM. Etravirine. Drugs. 2008;68(16):2357-2372.
13. Azijn H, Tirry I, Vingerhoets J, et al. TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1. Antimicrob Agents Chemother. 2010;54(2):718-727.
14. Lewis W, Day BJ, Copeland WC. Mitochondrial toxicity of NRTI antiviral drugs: an integrated cellular perspective. Nat Rev Drug Discov. 2003;2(10):812-822.
15. Goebel F, Yakovlev A, Pozniak AL, et al. Short-term antiviral activity of TMC278-a novel NNRTI, in treatment-naive HIV-1-infected subjects. AIDS. 2006;20(13):1721-1726.
16. European Medicines Agency. Edurant® 25 mg Film-Coated Tablets: Summary of Product Characteristics. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002264/WC500118874.pdf. Accessed December 9, 2011.
17. Lachau-Durand S, Mamidi RNVS, Cuyckens F, et al. Absorption, metabolism and excretion of TMC278, a next-generation non-nucleoside reverse transcriptase inhibitor (NNRTI), after a single oral dose of 150 mg in healthy male volunteers. 12th European AIDS Conference; November 11-14, 2009; Cologne, Germany. Abstract no PE7.1/3.
18. European Medicines Agency. Eviplera™ 200mg/25mg/245mg film coated tablets: Summary of product characteristics. Available from http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002312//WC500118802.pdf. Accessed February 25, 2013.
19. Gilead Sciences, Inc; Complera™: US Prescribing Information. Available from: www.gilead.com/medicines#hivaids. Accessed February 25, 2013.
20. Islam FM, Wu J, Jansson J, Wilson DP. Relative risk of renal disease among people living with HIV: a systematic review and meta-analysis. BMC Public Health. 2012;12(1):234.
21. Young J, Schäfer J, Fux CA, et al; Swiss HIV Cohort Study. Renal function in patients with HIV starting therapy with tenofovir and either efavirenz, lopinavir or atazanavir. AIDS. 2012;26(5):567-575.
22. Scherzer R, Estrella M, Li Y, et al. Association of tenofovir exposure with kidney disease risk in HIV infection. AIDS. 2012;26(7): 867-875.
23. Pozniak AL, Morales-Ramirez J, Katabira E, et al; TMC278-C204 Study Group. Efficacy and safety of TMC278in antiretroviral-naive HIV-1 patients: week 96 results of a phase IIb randomized trial. AIDS. 2010;24(1):55-65.
24. Molina JM, Cahn P, Grinsztejn B, et al; ECHO study group. Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial. Lancet. 2011;378(9787):238-246.
25. Cohen CJ, Andrade-Villanueva J, Clotet B, et al; THRIVE study group. Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial. Lancet. 2011;378(9787):229-237.
26. Rimsky L, Vingerhoets J, Van Eygen V, et al. Genotypic and phenotypic characterization of HIV-1 isolates obtained from patients on rilpivirine therapy experiencing virologic failure in the phase 3 ECHO and THRIVE studies: 48-week analysis. J Acquir Immune Defic Syndr. 2012;59(1):39-46.
27. de Mendoza C, Anta L, García F, et al. HIV-1genotypic drug resistance interpretation rules-2009 Spanish guidelines. AIDS Rev. 2009; 11(1):39-51.
28. Brochot A, Vis P, Corbett C, et al. Generalized additive modelling of virologic response to the NNRTIs rilpivirine (RPV, TMC278) and efavirenz (EFV) in treatment-naive HIV-infected patients: pooled week 48 data from ECHO and THRIVE. 13th European AIDS Conference; October 12-15, 2011; Belgrade, Serbia. Abstract no PS12/7.
29. Nelson M, Behrens G, Cohen C, et al. Sustained efficacy with low and similar rates of virologic failures in second year observed with rilpivirine (RPV) versus efavirenz (EFV) plus emtricitabine/tenofovir DF (FTC/TDF) in treatment-naive, HIV-1infected adults: pooled 96-week ECHO and THRIVE analysis. 13th European AIDS Conference (EACS); October 12-15, 2011; Belgrade, Serbia. Abstract no LBPE7.3/7.
30. Behrens G, Rijnders B, Nelson M, et al. Efficacy and safety outcomes for rilpivirine (RPV) versus efavirenz (EFV) plus emtricitabine/tenofovir DF (FTC/TDF) in treatment-naïve, HIV-1-positive adults with baseline viral load ≤ 100,000 copies/mL-pooled 48-week ECHO and THRIVE analysis. AIDS 2012: XIX International AIDS conference; July 22-27, 2012; Washington, DC. Abstract no TUPE023.
31. White K, Van Eygen V, Vingerhoets J, et al. Week 96 resistance analysis of the pooled ECHO and THRIVE Truvada subset in treatment-nai{dotless}ïve HIV-infected adults with #100,000 c/mL baseline viral load. 18th Annual Conference of the British HIV Association; April 18-20, 2012; Birmingham, UK. Abstract no P187.
32. Mathias A, Menning M, Wei X, et al. Bioequivalence of the co-formulation of emtricitabine/rilpivirine/tenofovir DF. 18th International AIDS Conference; July 18-23, 2010; Vienna, Austria. Abstract no LBPE17.
33. Cohen CJ, Wohl D, Arribas J, et al. STAR study: single-tablet regimen emtricitabine/rilpivirine/tenofovir DF is non-inferior to efavirenz/emtricitabine/tenofovir DF in ART-naive adults. 11th International Congress on Drug Therapy in HIV infection; November 11-15, 2012; Glasgow, UK. Abstract no O425.
34. Fisher M, Palella F, Tebas P, et al. SPIRIT study: switching boosted PI to Rilpivirine In combination with Truvada as an STR adults. 11th International Congress on Drug Therapy in HIV infection; November 11-15, 2012; Glasgow, UK. Abstract no P285.
35. Mills A, Cohen C, DeJesus E, et al. Virologic suppression is maintained in virologically suppressed HIV-1infected subjects switching from efavirenz/emtricitabine/tenofovir (EFV/FTC/TDF) single-tablet regimen (STR) to emtricitabine/rilpivirine/tenofovir (FTC/RPV/TDF) STR: week-24 results of GS-111. 18th Annual Conference of the British HIV Association (BHIVA); April 18-20, 2012; Birmingham, UK. Abstract no P186.
36. Cohen CJ, Molina JM, Cahn P, et al; ECHO Study Group; THRIVE Study Group. Efficacy and safety of rilpivirine (TMC278) versus efavirenz at 48 weeks in treatment-naive HIV-1-infected patients: pooled results from the phase 3 double-blind randomized ECHO and THRIVE Trials. J Acquir Immune Defic Syndr. 2012;60:33-42.
37. Mills A, Antinori A, Clotet B, et al. Neurologic and psychiatric safety profile of TMC278 compared with EFV in treatment-naive HIV-1+ patients: ECHO and THRIVE trials at 48 weeks. 18th Conference on Retroviruses and Opportunistic Infections; February 27-March 2, 2011; Boston, MA. Abstract no 420.
38. Rashbaum B, Girard P, Rachlis A, et al. Rilpivirine (RPV, TMC278) tolerability over the first 12 weeks of treatment in the phase 3 ECHO and THRIVE studies. 51st Interscience Conference on Antimicrobial Agents and Chemotherapy; September 17-20, 2011; Chicago, IL. Abstract no H2-805.
39. Vanveggel S, Buelens A, Crauwels H, et al. TMC27825mg/qd has no effect on corrected QT (QTC) interval in HIV-negative volunteers. 47th Annual Meeting of the Infectious Diseases Society of America; October 29-November 1, 2009; Philadelphia, PA. Abstract no 285.
40. Wohl D, Doroana M, Orkin C, et al. Change in vitamin D levels smaller and risk of development of severe vitamin D deficiency lower among HIV-1-infected, treatment-naive adults receiving TMC278 compared with efavirenz: 48-week results from the phase III ECHO trial. 18th Conference on Retroviruses and Opportunistic Infections; February 27-March 2, 2011; Boston, MA. Abstract no O1014.
41. Arribas J, Andrade-Villanueva J, Bellos N, et al. Lipid profiles of TMC278 and efavirenz in treatment-naïve, HIV-1-infected patients: pooled Week 48 data from the randomized, double-blind, Phase III ECHO and THRIVE trials. 18th Conference on Retroviruses and Opportunistic Infections; February 27-March 2, 2011; Boston, MA. Abstract no 0304.
42. Cohen CJ, Molina JM, Cassetti I, et al. Pooled week 96 efficacy, resistance and safety results from the double-blind, randomised, phase III trials comparing rilpivirine (RPV) versus efavirenz (EFV) in treatment-naive, HIV-1-infected adults. 6th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention; July 17-20, 2011; Rome, Italy. Abstract no TULBPE032.
43. Parienti JJ, Bangsberg DR, Verdon R, Gardner EM. Better adherence with once-daily antiretroviral regimens: a meta-analysis. Clin Infect Dis. 2009;48(4):484-488.
44. Nachega JB, Mugavero MJ, Zeier M, Vitória M, Gallant JE. Treatment simplification in HIV-infected adults as a strategy to prevent toxicity, improve adherence, quality of life and decrease healthcare costs. Patient Prefer Adherence. 2011;5:357-367.
45. Airoldi M, Zaccarelli M, Bisi L, et al. One-pill once-a-day HAART: a simplification strategy that improves adherence and quality of life of HIV-infected subjects. Patient Prefer Adherence. 2010;4: 115-125.
46. Bae JW, Guyer W, Grimm K, Altice FL. Medication persistence in the treatment of HIV infection: a review of the literature and implications for future clinical care and research. AIDS. 2011;25(3):279-290.
47. Willig JH, Abroms S, Westfall AO, et al. Increased regimen durability in the era of once-daily fixed-dose combination antiretroviral therapy. AIDS. 2008;22(15):1951-1960.
48. Colombo GL, Colangeli V, Di Biagio A, Di Matteo S, Viscoli C, Viale P. Cost-effectiveness analysis of initial HIV treatment under Italian guidelines. Clinicoecon Outcomes Res. 2011;3:197-205.
49. Colombo GL, Di Matteo S, Maggiolo F. Antiretroviral therapy in HIV-infected patients: a proposal to assess the economic value of single tablet regimen. Clinicoecon Outcomes Res. 2013;5:59-68.
50. Rizzardini G, Restelli U, Bonfanti P, et al. Cost of human immunodeficiency virus infection in Italy, 2007-2009: effective and expensive, are the new drugs worthwhile. Clinicoecon Outcomes Res. 2012;4:245-252.
51. Maggiolo F, Di Matteo S, Masini G, et al. Cost-effectiveness analysis of first line HAART. 11th International Congress on Drug Therapy in HIV infection; November 11-15, 2012; Glasgow, UK. Abstract no P096.
52. Lyseng-Williamson KA, Scott LJ. Emtricitabine/rilpivirine/tenofovir disoproxil fumarate single-tablet regimen: a guide to its use in HIV-1 infection. Clin Drug Investig. 2012;32(10):715-722.